# OnCo record alentis-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/alentis-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "alentis-therapeutics" ;
  schema:name "Alentis Therapeutics"@en ;
  schema:description "Alentis Therapeutics targets Claudin-1, a protein exposed on squamous cancers and scarred organs, with antibodies that either carry a cancer-killing drug or block disease signalling. Its first cancer medicine entered human trials in 2025."@en ;
  schema:url <https://onco.cc/companies/alentis-therapeutics/>, <https://alentis.ch/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://alentis.ch/>, <https://alentis.ch/alentis-therapeutics-raises-181-4-million-in-an-oversubscribed-series-d-financing-to-advance-the-clinical-development-of-anti-claudin-1-adcs-in-solid-tumors/>, <https://alentis.ch/news/> ;
  schema:addressCountry "CH" ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:trials <https://onco.cc/trials/nct07169734/>, <https://onco.cc/trials/nct06747585/> .